Advice You
#1 in Business Subscribe Email Print

You are here: Home > Finance > Finance > Property Rights and the EU

Tags

  • between
  • their
  • problems
  • companies involved
  • european union
  • companies involved

  • Links

  • Secured Loans: Class Financial Pursuit
  • Five Simple Steps to Install Laminate Wood Flooring
  • Committed to Nothing
  • Advice You - Property Rights and the EU

    The European Community (also referred to as the European Economic Community) has as its task the establishment of a common market and the progressive approximation of the e
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    conomic policies of Member States. The term common market has been defined as an area, which consists of two or more Member States that abolish tariffs and other trade barr
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    iers in their mutual trade, set-up a Common External Tariff with third non-EU countries and apply the principle of the free movement of the sources of production (goods, la
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    or, capitals) within the territory of that area.

    One of the fundamental principles of the European Union is the free movement of goods between Member States. Thus, Member
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    States are prohibited from imposing any restriction on imports or exports might hinder the free movement unless EC Law allows it. The European Union's Institutions through
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    their instruments and law regulations strive to develop a free commercial network that does not suffer from custom duties, quantitative restrictions, or other charges havin
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    equivalent effect on imports or exports.

    While Member States impose these kinds of restrictions in order to protect their own interests, the Court of Justice, through its
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    decisions, acts to ensure that EC Laws are applied. Free movement of goods means in practice that no regulations or restrictions take place on Member States' borders as Ar
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    ticles 25, 28 & 29 (ex Articles 12, 30 & 34) prohibit them. Specifically, while European Union Members try to impose restrictions of non-pecuniary or pecuniary nature on bo
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    ders, the Court of Justice acts a "guard" by examining the legal basis and the purpose of the charge imposed.

    Such restrictions or prohibitions shall not, however, constit
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    ute a means of arbitrary discrimination or a disguised restriction on trade between Member States. A Member State may have resource to Article 30 (ex Article 36) of the Tre
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    aty providing for the said exceptions to justify a measure having equivalent effect to quantitative restriction on imports or exports only if no other measure, less restric
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    ive from the point of view of the free movement of goods, is capable of achieving the same objective.

    Although the Treaty does not provide any exceptions, the Court has he
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    ld in the past, that charges levied for tasks required by EC Law or charges for services rendered, do not breach Article 25 (ex Article 12). Regarding Articles 28 & 29 (ex
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    Articles 30 & 36), the Court has introduced an exception called the Rule of Reason. It permits that restrictions can be imposed on goods as long as the Court of Justice all
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ws them.

    Concluding, the burden of proof that a measure is justified lies on the Member State's concern and on the Court of Justice's decision. In the case of industrial a
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    nd commercial property rights litigation between private parties, the burden lies on the party seeking to oppose the importation or sale of the product concerned. Save meas
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    ures relating to the protection of public policy or public morality, the adoption of other measures banning circulation of products and being able to jeopardize the free mo
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    ement of goods lawfully marketed in another Member State, obliges the Member States concerned to exchange information with the Commission so that the latter to be enabled t
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    o manage such measures affecting the free movement of goods and settle satisfactorily for business and consumers any problems arising in connection with the internal market


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.adviceyou.org.ua/article/89945/adviceyou-Property-Rights-and-the-EU.html">Property Rights and the EU</a>

    BB link (for phorums):
    [url=http://www.adviceyou.org.ua/article/89945/adviceyou-Property-Rights-and-the-EU.html]Property Rights and the EU[/url]

    Related Articles:

    Motivation and Need Fulfillment: An Art in Itself

    Mortgage Marketing - How to Write a Mortgage Marketing Sales Letter That Gets Results!

    Wholesale Video Games: Can I Really Save Money?

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com

    najlepsze odżywki nlp spływy kajakowe prezenty monety